BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Increase in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.7% from the August 31st total of 139,200 shares. Based on an average trading volume of 270,600 shares, the days-to-cover ratio is presently 0.7 days.

BioLineRx Stock Performance

Shares of NASDAQ:BLRX traded down $0.01 during midday trading on Friday, reaching $0.62. 145,924 shares of the company’s stock traded hands, compared to its average volume of 333,238. The company has a market cap of $49.56 million, a price-to-earnings ratio of -0.82 and a beta of 1.46. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. BioLineRx has a one year low of $0.51 and a one year high of $2.03. The stock has a 50 day moving average of $0.69 and a 200 day moving average of $0.72.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. As a group, equities research analysts anticipate that BioLineRx will post -0.25 EPS for the current fiscal year.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,840 shares of the biotechnology company’s stock, valued at approximately $97,000. BioLineRx makes up 0.5% of PVG Asset Management Corp’s holdings, making the stock its 29th biggest position. PVG Asset Management Corp owned approximately 0.09% of BioLineRx as of its most recent SEC filing. 1.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, June 3rd.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.